ETF Securities launches CURE ETF

ETF Securities has launched its new CURE exchange-traded fund (ETF) on the Australian Securities Exchange (ASX), which will offer investors exposure to healthcare biotechnology companies.

CURE would follow the S&P Biotechnology Select Industry Index, which according to the company, achieved annual growth of 21.9 per cent in Australian dollar terms over the five years to 31 October 2018.

Additionally, the fund would hold more than 120 biotechnology firms in its portfolio, with a focus on small and mid-cap companies. The fund’s fee would stand at 0.45 per cent.

Related News:

Head of ETF Securities Australia, Kris Walesby, said: “This is very much a high growth-oriented product.”

“Given the mainly mid- and small-cap profiles of the constituent stocks, we’d expect to see profitable M&A activity. We are pleased to be adding CURE to our ‘Future Present’ series of ETFs.”

Walesby also stressed that there would be demanding filters to be met before a company can be included in CURE, with companies needing to meet S&P Dow Jones Indices’ Float Adjustment liquidity requirements.

Related Content

ETF Securities fund upgraded by Zenith

ETF Securities has announced that its ETFS Physical Gold (GOLD) fund has been upgraded by research house, Zenith Investments Partners, to “recommend...Read more

Fidelity launches first active ETF in Australia

Fidelity International has announced the launch of its first active exchange-traded fund (ETF) in Australia, the Fidelity Global Emerging Markets Fund...Read more

DomaCom and DFS Portfolio Solutions launch sub-fund

DomaCom has announced an allocation to two mortgage investments by DFS Portfolio Services (DFSPS) branded Mortgage Fund, with approximately $4.1 milli...Read more



Add new comment